News Search Results
May 27, 2025, 10:00 ET Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics
May 27, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics, Inc. ("SiteOne"), a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, today announced a
More news about: Eli Lilly and Company
May 27, 2025, 10:00 ET ASU partners with biotech luminary and alum Mark McKenna to launch preeminent life science business program
McKenna is well-known for his leadership as chairman, president, and CEO of Prometheus Biosciences. Under his direction, the clinical-stage biotechnology company raised more than $1 billion in financing, launched the first precision therapeutics clinical trial for immune-mediated
More news about: W. P. Carey School of Business at Arizona State University
May 27, 2025, 09:00 ET Visionary Holdings' Changle Shuang Carries Out Biotechnology Health Public Welfare Activities for Society
content:https://www.prnewswire.com/news-releases/visionary-holdings-changle-shuang-carries-out-biotechnology-health-public-welfare-activities-for-society-302465782.html
More news about: Visionary Holdings Inc
May 27, 2025, 09:00 ET Maryland Businesses Celebrate New Leadership and Local Investments
through its vast pool of resources and investment funds; recent investments include those to Irazú Oncology, Hememics Biotechnologies, Inc., Neuros Biotechnology, Inc., Din Din, Inc., and
More news about: Maryland Marketing Partnership
May 27, 2025, 08:33 ET GlycoNex Announces Publication of Research Involving Pro-Antibody, GNX201, in the International Journal of Biological Macromolecules
GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced the publication of a peer-reviewed study in the International
More news about: GlycoNex, Inc.
May 27, 2025, 08:30 ET STORM Therapeutics Announces First Patient Dosed in Clinical Collaboration to Evaluate STC-15 in Combination with LOQTORZI® and Appointment of Atif Abbas, M.D., as Chief Medical Officer
combination studies with checkpoint inhibitors, such as LOQTORZI. About STORM Therapeutics STORM Therapeutics is a clinical-stage biotechnology company pioneering cellular reprogramming through RNA modifications to treat disease. Its world leading understanding of RNA modifying enzymes (RME)
More news about: STORM Therapeutics
May 27, 2025, 08:00 ET Sapience Therapeutics Announces Participation in the Jefferies Global Healthcare Conference
N.Y., May 27, 2025 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, today
More news about: Sapience Therapeutics, Inc.
May 27, 2025, 06:30 ET Lupin Announces Presentation of Phase 1 Data on LNP7457 (PRMT5 inhibitor) at the American Society of Clinical Oncology - Annual Meeting 2025
products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position
More news about: Lupin Limited
May 26, 2025, 10:15 ET Healthcare Contract Manufacturing Market Size worth $347.5 Billion, Globally, by 2030 - Exclusive Report by The Research Insights
driven primarily by pharmaceutical, biotechnology, and medical device companies seeking ways to lower operational expenses while enhancing production efficiency. Healthcare companies benefit from
More news about: The Research Insights
May 26, 2025, 10:15 ET Network Slicing Market worth $49.82 billion by 2030- Exclusive Report by MarketsandMarkets™
medical imaging, intelligent ambulances, and wearables to work in essential sites that require strength in data transmissions. Pharmaceutical and biotechnology organizations use dedicated slices to guarantee smooth and safe transfers of data across their sites involved in clinical research, as well as AI-related
More news about: MarketsandMarkets
May 25, 2025, 20:00 ET Phase 3 Clinical Study of Mazdutide in Chinese Adults with Overweight or Obesity (GLORY-1) Published in The New England Journal of Medicine (NEJM)
China has been published in NEJM, a milestone that highlights China's growing capabilities in drug development and biotechnology innovation. This publication is expected to contribute to the evolving global clinical guidelines for the treatment of overweight and obesity.
More news about: Innovent Biologics
May 23, 2025, 13:47 ET Veterinary Diagnostics Market to Reach Nearly $6 Billion by 2029 -- Kalorama Information
InformationKalorama Information, part of the Science and Medicine Group, is a leading publisher of market research in in vitro diagnostics, biotechnology, and medical devices. For over 20 years, Kalorama has delivered trusted intelligence to help healthcare organizations make informed decisions.
More news about: Kalorama Information
May 23, 2025, 13:47 ET Celltrion's YUFLYMA® (adalimumab-aaty) receives FDA interchangeability designation for all its approved dosage forms and strengths
ZYMFENTRA® (infliximab-dyyb). Celltrion USA will continue to leverage Celltrion's unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information,
More news about: Celltrion
May 23, 2025, 13:44 ET Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote "FOR" All Four of Dynavax's Highly Qualified Director Nominees
Lauren Silvernail and Elaine Sun – bring proven strategic leadership, vaccine expertise, senior public biotechnology and M&A experience and deep industry financial expertise, all of which are critical to Dynavax. Replacing any of our directors with Deep Track's
More news about: Dynavax Technologies
May 23, 2025, 09:08 ET Liebherr expands scientific portfolio with new combination refrigerator-freezer for research and laboratory needs
freezers introduces new combination refrigerator-freezer expanding current scientific and healthcare portfolio to meet the needs of healthcare, biotechnology and pharma industries. MIAMI,
More news about: Liebherr Appliances USA
May 23, 2025, 07:18 ET UniXell Biotechnology announces the first patient dosed with UX-DA001, an investigational autologous iPSC based cell therapy for the treatment of Parkinson's disease, in its Phase 1 study
More information about this trial is available at clinicaltrials.gov (NCT#06778265). About UniXell Biotechnology Co., Ltd. Shanghai UniXell Biotechnology Co., Ltd. was established in 2021, specializing in the research and development of cell therapy drugs for neurological
More news about: UniXell Biotechnology
May 23, 2025, 07:00 ET SystImmune, Inc. to Present New izalontamab brengitecan (iza-bren) Data in Small Cell Lung Cancer and Non-Small Cell Lung Cancer with Driver Genomic Alterations (GA) outside of Classic EGFR Mutations at ASCO Congress 2025
May 23, 2025 /PRNewswire/ -- SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced that two abstracts on izalontamab brengitecan (iza-bren), a potentially first-in-class EGFRxHER3 bispecific antibody drug
More news about: SystImmune, Inc.
May 23, 2025, 07:00 ET Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities
and has established itself both nationally and internationally. About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized
More news about: Oncolytics Biotech® Inc.
May 23, 2025, 00:21 ET Nona Biosciences Collaboration Partner Pfizer Announces Presentation of Phase 1 Clinical Study Design on MesoC2, an MSLN-Targeting ADC, at the 2025 ASCO Annual Meeting
Mass., May 23, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), today announced that its collaborator,
More news about: Nona Biosciences
May 22, 2025, 22:44 ET FDA Clearance of Investigational New Drug Application Received for Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418
2025 /PRNewswire/ -- Duality Biotherapeutics ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced clearance by the U.S. Food and Drug Administration (FDA) of its investigational
More news about: Duality Biotherapeutics
May 22, 2025, 20:00 ET Eisai to Present E7386, Co-created by PRISM BioLab and Eisai, at the ASCO (American Society of Clinical Oncology) Annual Meeting
May 22, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that the analysis of a combination study
More news about: PRISM BioLab Co., Ltd.
May 22, 2025, 19:05 ET Rakuten Medical Announces Trial in Progress Poster Presentation at ASCO 2025 and Enrollment Expansion to Taiwan for Global Phase 3 ASP-1929-381
DIEGO, May 22, 2025 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, today announced that it will present a Trial in Progress poster
More news about: Rakuten Medical, Inc.
May 22, 2025, 18:50 ET ASCO Study Abstract Shows Cizzle Bio's CIZ1B Biomarker Test for Lung Cancer Could Save $518M in Annual Medicare Costs
www.asco.org/abstracts. About Cizzle Bio, Inc. Cizzle Bio is a Texas-based biotechnology company dedicated to revolutionizing cancer diagnostics by pioneering biomarker-based blood tests, starting with early detection of lung and gastric
More news about: Cizzle Bio
May 22, 2025, 17:20 ET Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress
May 22, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced seven upcoming poster presentations at the 2025 American Society of Clinical
More news about: Rigel Pharmaceuticals, Inc.
May 22, 2025, 17:05 ET Lilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company